 At present, dosing in cohorts 1 through 5 has been completed with dosing in cohort 6 scheduled to begin shortly. No evidence of dose-limiting toxicities was observed in the latest dose cohort cohort 5. A dose-limiting toxicity was observed in 1 of 6 patients in cohort 4. 